3D Printed Drugs Market

3D Printed Drugs Market Size and Growth Rate:

According to our research report, the Printed Drugs Market size is poised to reach USD 342 million by the end of 2025 from USD XX Billion in 2017 and this market witnessed a growth rate of XX% during the forecast period 2017-2025.

3D Printed Drugs Market Growth Drivers and Restraints:

Recent approval of 3D printed drugs has created immense opportunities for pharmaceuticals and biotechnology industry in the near future. Currently, there is only one 3D printed drug, Spritam, present in the market. Spritam is a 3D printed drug launched by Aprecia Pharmaceuticals to treat epilepsy. It has received FDA approval in 2016, and is currently active only in the U.S. region. The core objective of a 3D printed drug is to offer personalized medication to individuals in terms of dosage, size, appearance and others. The technology is also anticipated to have potential to create significant innovations in Cancer treatment, Obesity and other critical diseases. However, concerns such as blueprint hacking and mislabeling of blueprint are going to hamper the market growth. Moreover, dicey regulatory scenario is another major restraint.

3D Printed Drugs Market Regional Presence:

Currently Spritam is the only 3DP drug available in the market which is available only in the U.S. region, however will likely to launch in Europe and Asia Pacific by 2022. Prevalence of dysphagia across the world.

Some of the Prominent Companies Operating the Global  3D Printed Drugs Market analyzed in the report are:

• Aprecia Pharmaceuticals,
• GlaxoSmithKline Plc
• Hewlett Packard Caribe
• BV
• LLC
• 3D Printer Drug Machine
• FabRx Ltd

The Research Report segments the Global 3D Printed Drugs Market into the following submarkets:

Global 3D Printed Drugs Market – By Drug:

• Spritam

• Others

Global 3D Printed Drugs Market – By Region:

• North America                                                 
• Europe                                                                                              
• Asia-Pacific                                                      
• Latin America                                                                              
• Middle-East & Africa